Back to Search
Start Over
Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia
- Source :
- Blood Advances; November 2023, Vol. 7 Issue: 21 p6492-6505, 14p
- Publication Year :
- 2023
-
Abstract
- •A dose-optimized schedule of priming, step-up, and target vibecotamab doses mitigated CRS while achieving response.•Low blast-count AML and low PD-1 expression on CD4+and CD8+T cells were associated with response to vibecotamab.
Details
- Language :
- English
- ISSN :
- 24739529 and 24739537
- Volume :
- 7
- Issue :
- 21
- Database :
- Supplemental Index
- Journal :
- Blood Advances
- Publication Type :
- Periodical
- Accession number :
- ejs63952302
- Full Text :
- https://doi.org/10.1182/bloodadvances.2023010956